---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046809"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:02:17.788818+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zai Lab Q3 net product revenue rises 47% YoY to $101.8M; KarXT bridging study positive

## Summary
- Net product revenue $101.8M, up 47% YoY; net loss $41.7M ($0.42/ADS loss).
- VYVGART sales $27.3M (vs $4.9M YoY); ZEJULA $48.2M (+16%); NUZYRA $10.0M (+82%).
- KarXT bridging study in schizophrenia met primary endpoint (9.2-point PANSS reduction, p=0.0014); NDA submission expected early 2025.
- ZL-1310 (DLL3 ADC) Phase 1 data shows 74% ORR in extensive-stage SCLC; potential best-in-class.
- Cash position $716.1M; three product launches in China expected by end of 2024.

## SEC filing metadata
- accession: 0001628280-24-046809
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828024046809/0001628280-24-046809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828024046809/zlab-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046809
- JSON: https://secwatch.observer/filing/0001628280-24-046809.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.